Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Pierre NahonClovis Lusivika-NzingaPhilippe MerleFabien ZoulimThomas DecaensNathalie Ganne-CarriéGeorges-Philippe PageauxVincent LeroyLaurent AlricJean-Pierre BronowickiMarc BourlièreJérôme GournayAlbert TranStanislas PolPhilippe MathurinVéronique Loustaud-RattiSophie MétivierVictor de LedinghenArmand AbergelDominique ThabutLouis d'AlterocheMohammed BouattourTarik AsselahDenis OuzanPaul CalesOlivier ChazouillèresMoana Gelu-SimeonDominique RoulotJérôme BoursierCarole CagnotSonia TamazirtAlina PascaleSamuel NilusmasMaïté LewinMarianne ZiolFabrice CarratJean‐charles Duclos-Vallée
• Organismes : Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Hôpital Avicenne [AP-HP] Centre de Recherche des Cordeliers Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) Hôpital Henri Mondor Pharmacochimie et Biologie pour le Développement Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy] Hôpital Saint-Joseph [Marseille] Institut des Maladies de l'Appareil Digestif Centre Hospitalier Régional Universitaire [CHU Lille] Université Côte d'Azur Hôpital Archet 2 [Nice] Centre méditerranéen de médecine moléculaire Service d'hépatologie médicale [CHU Cochin] Université Paris Descartes - Paris 5 Institute for Translational Research in Inflammation - U 1286 Biologie moléculaire et cellulaire des microorganismes Service de Bactériologie, Virologie, Hygiène [CHU Limoges] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Université de Bordeaux CHU Clermont-Ferrand CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en épidémiologie et santé des populations Sorbonne Université Centre Hospitalier Régional Universitaire de Tours Hôpital Beaujon [AP-HP] Centre de recherche sur l'Inflammation Hôpital Beaujon [AP-HP] Centre de recherche sur l'Inflammation Institut Arnault Tzanck Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers CHU Saint-Antoine [AP-HP] Institut de recherche en santé, environnement et travail CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre de Recherche des Cordeliers AP-HP - Hôpitaux Universitaires Paris Seine-Saint-Denis Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Centre Hospitalier Universitaire d'Angers CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble ANRS - Maladies infectieuses émergentes Physiopathologie et traitement des maladies du foie Physiopathologie et traitement des maladies du foie Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre Hépato-Biliaire [Hôpital Paul Brousse] Assistance publique - Hôpitaux de Paris (AP-HP) Centre de Recherche des Cordeliers Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Physiopathogénèse et Traitement des Maladies du Foie
• Publié dans Journal of Hepatology le 23/10/2020

---

Résumé : Background & aims: Whether the dynamics of non-invasive tests (NITs) correlate with hepatocellular carcinoma (HCC) risk in patients with cirrhosis following sustained virological response (SVR) remains unknown. Thus, we aimed to describe NIT dynamics and assess their correlation with HCC risk. Methods: The dynamics of NITs (fibrosis-4 index [FIB-4], aspartate aminotransferase-to-platelet ratio index [APRI] and liver stiffness measurement) were described in patients with cirrhosis after SVR included in two prospective French multicenter cohorts (ANRS CO22 Hepather and CO12 CirVir) between 2006 and 2015. To assess their relationship with the risk of HCC, a joint modeling approach was employed using both standard and flexible models adjusted for age and sex. The impacts of NIT current value and slope during follow-up on HCC risk were assessed, considering competing risks of death. Results: A total of 3,067 patients with cirrhosis who achieved SVR were analyzed, among whom 228 (7.4%) developed HCC and 210 (6.9%) died during a 26-month follow-up. All NITs were increased at baseline in patients who ultimately developed HCC, whereas platelet counts were lower. All NITs improved in patients who did not develop HCC. More varied changes were observed during the follow-up of patients who ultimately developed HCC. Joint model analyses showed that current values of FIB-4, APRI and platelet count at any time impacted HCC risk. Only FIB-4 and APRI slopes influenced the same outcome. When considering NIT current value and slope simultaneously, only the current value of NITs impacted HCC risk while the slopes were not informative. Conclusions: The dynamics of NITs following SVR do not identify patients with cirrhosis who could be safely excluded from surveillance programs. NIT current value is more informative than slope, which will necessitate regularly re-assessment of HCC risk to design individualized surveillance strategies. Impact and implications: It has been postulated that monitoring non-invasive test (NIT) dynamics following HCV cure may provide information on the residual risk of hepatocellular carcinoma (HCC) in patients with cirrhosis and may allow for the discontinuation of surveillance in certain patient subsets. We analyzed data from over 3,000 patients and found that while all NITs improved in patients with cirrhosis who did not develop HCC, those who eventually developed liver cancer showed more varied changes in these tests. Specifically, the current values of tests like FIB-4 (fibrosis-4 index) and APRI (aspartate aminotransferase-to-platelet ratio index) were linked to an increased risk of HCC, while their slopes did not provide additional useful information, suggesting that dedicated prospective studies are warranted to define how repeated measurement of NITs could be combined with other variables into HCC risk stratification algorithms. Until then, HCC surveillance should be maintained in all patients with cirrhosis following HCV eradication, even in case of decreased NIT values.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2025
• Auteurs : Nicolas BonfantiP. CholerJean-Christophe ClementPierre BarréFrançois BaudinLauric CecillonAmélie SaillardWilfried ThuillerJérôme PoulenardNorine KhedimRomain Goury
• Organismes : Environnements, Dynamiques et Territoires de Montagne Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire d'Ecologie Alpine Centre Alpin de Recherche sur les Réseaux Trophiques et Ecosystèmes Limniques Laboratoire de géologie de l'ENS Institut des Sciences de la Terre de Paris Laboratoire de géologie de l'ENS Ambassade de France au Kénya Laboratoire d'Ecologie Alpine Laboratoire d'Ecologie Alpine Environnements, Dynamiques et Territoires de Montagne Environnements, Dynamiques et Territoires de Montagne Laboratoire d'Ecologie Alpine
• Publié dans Geoderma le 25/10/2020

---

Résumé : Estimating SOC stocks and stability, as well as modeling their response to rising temperatures, is crucial for predicting climate change impacts. This is particularly true in mountainous regions, where low temperatures slow down SOC decomposition, resulting in higher SOC stocks compared to soils at lower elevations. However, these stocks are also more vulnerable to warming, increasing the risk of SOC depletion. Such conditions create the potential for a positive feedback loop in which warming accelerates SOC losses, further amplifying climate change impacts on these sensitive ecosystems. To better understand the factors controlling SOC stocks and stability in mountain soils, we sampled 170 soil profiles along 29 elevation gradients in the western Alps from 280 to 3160 m a.s.l. We assessed SOC stocks and chemical composition using mid-infrared spectroscopy method and SOC stability with Rock-Eval® thermal analysis. Our findings, based on an unprecedented dataset, reveal a clear elevational pattern in SOC properties. SOC stocks increase with elevation up to the montane belt (1200–1500 m a.s.l.), remain relatively stable through the subalpine zone, and then decline beyond the subalpine/alpine boundary (2200–2400 m a.s.l.). Notably, this transition is also marked by a significant drop in SOC stability, suggesting a shift in the dominant stabilization processes at higher elevations. Our results also indicate that SOC stocks and stability are influenced by a complex interplay of factors. At higher elevations, climate emerges to be the dominant factor, whereas lithology and weathering play a more significant role at lower elevations. These results suggest that at high-elevations, harsh climatic conditions favor stabilization of SOC, while less developed soils limit organo-mineral interactions. In contrast, at warmer, lower elevations with higher carbon fluxes, more developed soils facilitate organo-mineral interactions, thereby enhancing SOC stability in the long term. Consequently, alpine grasslands, which contain substantial stocks of labile carbon stabilized by climatic conditions, appear to be particularly vulnerable to the effects of climate warming.

---

Fichiers liés : 1-s2.0-S0016706125002939-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/08/2025
• Auteurs : David Messika-ZeitounMichael W.A. ChuDenis BouchardThierry Le TourneauJulien TernaclePhilippe DemersLinrui GuoAngel Yi Nam FuJean Claude DibCharmaine LamThays SokolovAmedeo AnselmiDidier TchétchéOphélie Brault MeslinAnge GoutondjiYoan Lavie-BadiePatrick SeknadjiAugustin CoisneDimitri ArangalageAnne BernardUsha ManianMalek KassAntonio FioreArnaud MaudiereYohann BohbotAurélien SeemannNadjib HammoudiLoïc BièrePierre-Yves LerouxJessica ForcilloAntoine JeuBenjamin ElegamandjiChristine Selton-SutyMartine GilardClaire BouletiOmair ArshadJean-Francois LegareThiziri Si MoussiJian YeCatherine SportouchBindu BittiraLaura MunteFabrice BauerGéraldine OngAli Fatehi HassanabadJordan BernickGeorge WellsRoja GaudaBernard IungWilliam D.T. KentJean-François ObadiaJulien Dreyfus
• Organismes : University of Ottawa Heart Institute Western University [Ontario] Montreal Heart Institute - Institut de Cardiologie de Montréal ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 CHU de Bordeaux Pellegrin [Bordeaux] Montreal Heart Institute - Institut de Cardiologie de Montréal Western University [Ontario] University of Ottawa Heart Institute Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] University of British Columbia [Canada] Hospices Civils de Lyon Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Toulouse Hôpital Privé Jacques Cartier [Massy] Centre Hospitalier Régional Universitaire [CHU Lille] Laboratoire de Recherche Vasculaire Translationnelle Centre Hospitalier Régional Universitaire de Tours Membrane Signalling and Inflammation in reperfusion Injuries Hôpital Henri Mondor Hôpital Saint-Joseph [Marseille] Neurologie [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Nouvelle Clinique de Tours Saint Gatien-Alliance [Tours] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire d'Angers Médipôle Lyon-Villeurbanne Université de Montréal Hôpital Privé Le Bois Ramsay Santé [Lille] Centre cardiologique du Nord Centre Hospitalier Universitaire de Nancy Hôpital Maison Blanche Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] Dalhousie University [Halifax] Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion] St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] Clinique du Millénaire - Oc Santé [Montpellier] Health Sciences North Research Institute [Sudbury] Hôpital Européen Georges Pompidou [APHP] Hôpital Charles Nicolle [Rouen] University of Toronto University of Calgary University of Ottawa Heart Institute University of Ottawa Heart Institute Université d'Ottawa = University of Ottawa [Ontario] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Laboratoire de Recherche Vasculaire Translationnelle University of Calgary Hospices Civils de Lyon Centre cardiologique du Nord
• Publié dans Circulation le 29/10/2020

---

Résumé : Background: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "allcomer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. Methods: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. Results: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51–131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). Conclusions: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2025
• Auteurs : Marie AndréJulien KirchgesnerDavid LaharieLucas GuilloPhilippe SeksikLaurent AbramowitzMathurin FumeryPauline WilsMorgane AmilStéphane NanceyCatherine Le BerreA. BuissonNadia FathallahCyrielle Gilletta de Saint JosephMathieu UzzanDriffa MoussataNicolas DuveauLaurent Peyrin‐BirouletStéphane NahonNicolas RichardMaeva CharkaouiÉric VicautLucine Vuitton
• Organismes : Centre Hospitalier Régional Universitaire de Besançon Pharmacoépidémiologie et évaluation des soins [iPLesp] CHU Saint-Antoine [AP-HP] Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpital Nord [CHU - APHM] Aix Marseille Université Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Amiens-Picardie Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Hôpital Claude Huriez [Lille] Université de Lille Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre International de Recherche en Infectiologie Centre Hospitalier Lyon Sud [CHU - HCL] Institut des maladies de l'appareil digestif [Nantes] Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Clermont-Ferrand Hôpital Léopold Bellan Centre hospitalier Saint-Joseph [Paris] Centre Hospitalier Universitaire de Toulouse Hôpital Henri Mondor Université Paris-Est Créteil Val-de-Marne - Paris 12 Membrane Signalling and Inflammation in reperfusion Injuries Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier de Roubaix Nutrition-Génétique et Exposition aux Risques Environnementaux Service d'Hépato-gastro-entérologie [CHRU Nancy] Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Université de Rouen Normandie Service d'Hépato-Gastroentérologie [CHU Rouen] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal Centre Hospitalier Régional Universitaire de Besançon Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
• Publié dans The American Journal of Gastroenterology le 22/10/2020

---

Résumé : INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effectiveness and safety of SC IFX in pCD. METHODS: We conducted a multicenter retrospective cohort study from the GETAID, including patients with either active (group 1) or inactive (group 2) pCD when they started SC IFX. Inclusion criteria were, for group 1: active pCD in the 6 months before initiation of SC IFX; for group 2: inactive pCD for >6 months at the time of IV to SC switch. The primary end points were clinical remission at 6 months in group 1 and pCD relapse in group 2. RESULTS: Of the 183 patients included in 24 centers, 66 were in group 1 and 117 in group 2. The median follow-up was 50.4 (27.0–64.6) and 53.4 (40.6–67) weeks, respectively. In group 1 at 6 months, clinical remission was observed in 44.6% of patients and clinical response in 87.7%. Clinical remission including seton removal occurred in 35.5% of patients. In multivariable analysis, high body mass index was the only independent predictor of remission (odds ratio 0.88, 95% confidence interval 0.77–0.99). In group 2, rates of relapse-free survival were 94.3% and 87.9% at 6 and 12 months, respectively. Sixteen cases (8.3%) of adverse events related to SC injection were observed. DISCUSSION: SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2025
• Auteurs : Vincent GuiraudAntoine FauchoisCathia SouliéValentin LeducqMarianne VeyriLambert AssoumouDavid BoutolleauDominique CostagliolaOlivier LambotteJean-Philippe SpanoValérie PourcherAnne-Geneviève MarcelinVincent Calvez
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP]
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : Antibodies to programmed cell death 1 (PD-1), Programmed death-ligand 1 (PDL-1) and Cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4) can revert HIV latency and enhance anti-HIV cytotoxic response but their impact on HIV proviral sequences and integration landscape in people with HIV (PWH) remain to be studied. Two PWH treated with PD-1/PDL-1 and one with PD-1/CTLA4 were studied among the ANRS-CO-24 OncoVIHAC cohort study. Matched integration site and proviral sequencing were performed pre-and post-treatment. Immune checkpoint inhibitors (ICI) were not associated with significant changes in total cellassociated HIV-DNA, nor significant changes in genomic or epigenetic features of integration sites. ICIs were associated with a lesser proportion of proviruses with pol frameshifts for all regimen, with the PD-1 and PD-1/CTLA4 patients also experiencing a higher proportion of proviral sequences harboring gag frameshifts and a higher number of STOP codons, consistent with a gag-driven immune clearance. ICI use were consistently associated with a limited reduction in the HIV-reservoir diversity. Finally, the patient with a PD-1/CTLA4 treatment exhibited the loss of an HIV-clone in the NIN-oncogene representing 17% of all his pre-treatment sequences. Despite stable levels of cell-associated HIV DNA, ICI treatment can lead to modest changes in proviral sequence landscapes.

---

Fichiers liés : OncoVIHAC-papier-revised-unmarked.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/08/2025
• Auteurs : Ariel GraykowskiGuillaume LanginDavid ChironBruno GuilletF. MarchisNicolas BiverGérard ArlicBernard BaudouinEtienne BertrandRandall BlakeCyrille BosquetJohn BradleyIsabelle BrocardChristophe CacAlain CagnaNicolas CastelEric ChariotOlivier ClergetTom CoarraseLucas CogniauxJulien CollotChristophe CotéMichel DeconinckJean-Paul DesgreesJ. DesmarsGiuseppe Di TommasoJosé DonasWilliam DrapeaudTodd ForresterFlorent FremontKeiichi FukuiPaul GardeJérôme GaudillierePascal GaudinAlexis GiacomoniDavid GinestePatrice GirardJean Claude GomezChuck GoodmanGerard-Philippe GrandjeanPhilippe GuiglionDavid HavellPatrick HuthKachi IwaiMarc-Etienne JulienRachel KnightRyuichi KukitaPetri KuossariJean-Michel LadruzeAnis Ben LassouedCédric LatgéJean-Marie LaugierMatthieu LauvernierPatrice Le GuenJean-Charles Le TarnecDidier LefoulonLiouba LerouxNiniane LerouxArnaud LeroyChelsey LoganYohann LorandElisabeth MarisJean-Pierre MasiniNicola MeneghelliLaurent MillartEric MinyMike MitchellBaptiste MontoyaFabrice MortecretteAnouchka NardiAntoine NgoDenis NicolasRaphael NicolleratTakaya OkadaWataru OnoGeorge PatatoukasJacqueline Payet-AyraultPatrick PicardClaude PorchelKanai PottsMichel QuienenMartial RelierFabien RichardotDarren RivettMatthew RynoFadi SaibiSophie SaibiChristian SartiniHiromichi SasakiPhilippe SeibertMasao ShimizuLucas SifoniGeorges SimardPetri TikkanenIan TransomBernard TregonFrank TyrlikLaurent VadrotMichel VeuilletChristian VoirolStefan WillCorine YahiaPhil YehleNeil YoblonskyWai-Chun Yue
• Organismes : Search for Extraterrestrial Intelligence Institute Association Française d'Astronomie Club Eclipse : Club d'Etudes du Ciel, de la Lune, des Instruments, des Planètes, du Soleil et des Etoiles... Association Française d'Astronomie Unistellar Search for Extraterrestrial Intelligence Institute Unistellar Observatoire de Paris Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Institut Polytechnique des Sciences Avancées Laboratoire Temps Espace Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Association Française d'Astronomie Unistellar Unistellar Unistellar Unistellar Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Association Française d'Astronomie Unistellar Association Française d'Astronomie Unistellar Unistellar Unistellar
• Publié dans The Planetary Science Journal le 01/11/2020

---

Résumé : We report photometric observations of Comet 103P/Hartley 2 during its 2023 apparition. Our campaign, conducted from August through December 2023, combined data from a global network of citizen astronomers coordinated by Unistellar and the Association Française d'Astronomie. Photometry was derived using an automated pipeline for eVscope observations in partnership with the SETI Institute and aperture photometry via AstroLab Stellar. We find that the comet's peak reduced brightness, measured at G min = 10.24 ± 0.47, continues a long-term fading trend since 1991. The decline in activity follows a per-apparition minimum magnitude increase of ∆G min = 0.59 ± 0.11 mag, corresponding to a ∼42% reduction in brightness each return. This trend implies that the comet's active fraction has declined by approximately an order of magnitude since 1991 and may indicate that Hartley 2 is no longer hyperactive by definition. The fading is consistent with progressive volatile depletion rather than orbital effects. These results offer insight into the evolutionary processes shaping Jupiter-family comets.

---

Fichiers liés : 2508.20215v1.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/08/2025
• Auteurs : Florence JolyAlexandra LearyIsabelle Ray-CoquardBernard AsselainManuel Jorge RodriguesLaurence GladieffGuillaume MeynardSophie Abadie-LacourtoisieCoriolan LebretonLeïla Bengrine LefevrePierre FournelRémy LargillierFrédéric SelleJean-Sébastian FrenelYolanda Fernandez DiezCyril FoaPhilippe FollanaJérôme MeunierMichel FabbroAnne-Claire Hardy BessardIsabelle Cojean-ZelekEmilie KaczmarekElise BonnetAntoine ArnaudSophie RocheKaren LeroyPierre-Alexandre JustRaphaël LemanCorinne JeanneCéline CallensBenoit YouJérôme Alexandre
• Organismes : Research on Healthcare Performance
• Publié dans Nature Communications le 23/10/2020

---

Résumé : Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950). Female patients without progression following front-line platinum-based chemotherapy for advanced/metastatic endometrial cancer were randomized 2:1 to twice-daily maintenance oral olaparib 300 mg or placebo until progression or intolerance, stratified by p53 status, mismatch repair status, and response to initial chemotherapy. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Secondary endpoints were PFS in subgroups, time to second progression or death, time to first and second subsequent therapy, objective response rate, overall survival, patient-reported outcomes, and safety. In the intention-to-treat population (n = 145), there was no PFS difference between olaparib and placebo (median 5.6 vs. 4.0 months, respectively; hazard ratio 0.94, 95% confidence interval 0.65-1.35; p = 0.74). However, intriguing numerical PFS effects were observed in exploratory analyses of pre-specified subgroups (p53-abnormal, complete response to initial chemotherapy, chromosomal instability). There was no overall survival difference between treatments. Grade 3/4 adverse events occurred in 36% versus 10% of olaparib- versus placebo-treated patients and were consistent with the olaparib safety profile in other cancers. Maintenance olaparib did not improve PFS, but promising numerical effects in subsets of patients warrant prospective evaluation.

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 26/08/2025
• Auteurs : Ibrahim Jaser AbualrobShreyasi AcharyaGianluca Aglieri RinellaLuca AgliettaMichelangelo AgnelloNeelima AgrawalZubayer AhammedShakeel AhmadIshaan AhujaZulkaida AkbarAlexander AkindinovValentina AkishinaMohammad Al-TuranyDmitry AleksandrovBruno AlessandroHaidar Mas'Ud AlfandaJose Ruben Alfaro MolinaBushra AliAndrea AliciAnton AlkinJohan AlmeGiacomo AloccoTorsten AltAnna Rita AltamuraIgor AltsybeevCristian AndreiNicodemos AndreouAnton AndronicEvgeny AndronovVenelin AnguelovFederico AntinoriPietro AntonioliNicole ApadulaHarald AppelshaeuserSilvia ArcelliRoberta ArnaldiJhoao Gabriel Martins Campos Almeida ArneiroIonut Cristian ArseneMesut ArslandokAndre AugustinusRalf Peter AverbeckMohd Danish AzmiHitoshi BabaAkash Raj John BabuAngela BadalaJoonsuk BaeYunseul BaeYongwook BaekXiaozhi BaiRaphaelle Marie BailhacheYoshini BailungRenu BalaAlberto BaldisseriBartosz BalisShubham BangaliaZarina BanooVeronika BarbasovaFrancesco BarileLuca BarioglioMaria BarlouBanajit BarmanGergely Gabor BarnafoldiLee Stuart BarnbyEmilie Martine BarreauValerie Ramillien BarretLeonardo Barreto de Oliveira CamposKlaus BarthEsther BartschNicole BastidGuillaume BatigneDaniel BattistiniBoris BatyunyaDibakar BauriJose Luis Bazo AlbaIan Gardner BeardenPascal BechtDebadatta BeheraSwadhin BeheraIouri BelikovValerio Di BellaFrancesca BelliniRene BellwiedLucina Gabriela Espinoza BeltranYael Antonio Vasquez BeltranGyula BencediAdel BensaoulaStefania Maria BeoleYaroslav BerdnikovAnastasia BerdnikovaLuisa BergmannLorenzo BernardinisLatchezar BetevPartha Pratim BhaduriTushar BhallaAnju BhasinBuddhadeb BhattacharjeeSumit BhattaraiLivio BianchiJaroslav BielcikJana BielcikovaAnte BilandzicAnna BinoyGabor BiroSaikat BiswasDmitry BlauMihail Bogdan BlidaruNora BluhmeChristoph BlumeFriederike BockTea BodovaJeongsu BokLaszlo BoldizsarMarek BombaraPeter Matthew BondGermano BonomiHerve BorelAlexander BorissovAndres Gerardo Borquez CarcamoElena BottaYoussef El Mard BouzianiDiana Catalina BrandiburLars BratrudPeter Braun-MunzingerMarco BregantMichal BrozGiuseppe Eugenio BrunoValentin Dimitrov BuchakchievMatthew Daniel BucklandHenner BueschingStefania BufalinoPaul Alois BuhlerNazar BurmasovEdith Zinhle ButheleziAleksandr BylinkinChristopher Alfred CarrJuan Carlos Cabanillas NorisMaria Fernanda Torres CabreraHelen Louise CainesAlberto CalivaErnesto Calvo VillarJuan Manuel Mejia CamachoPaolo CameriniMaria Teresa CamerlingoFabio de Moraes CanedoStefano CannitoSierra Lisa CantwayMihai CarabasFrancesca CarnesecchiLeopoldo Abranches de CarvalhoJavier Ernesto Castillo CastellanosMatteo CastoldiFabio CatalanoSamuele CattaruzziRebecca CerriIrakli ChakaberiaPritam ChakrabortyJustin Wei Ong ChanSinjini ChandraSylvain ChapelandMarielle ChartierSouvik ChattopadhayMeiyi ChenTiantian ChengCvetan Valeriev CheshkovDavide ChiapparaVasco Miguel Chibante BarrosoDavid Dobrigkeit ChinellatoFabrizio ChinuEmma Sophia ChizzaliJaeyoon ChoSoyeon ChoPeter ChochulaZuzanna Anna ChochulskaDhrubajyoti ChoudhuryPanagiotis ChristakoglouChristian Holm ChristensenPeter ChristiansenTatsuya ChujoMario CiaccoCorrado CicaloGabriele CimadorFederico CindoloGiulia ClaiFabio Filippo ColamariaDomenico ColellaAngelo ColelliManuel ColocciMatteo ConcasGustavo Conesa BalbastreZaida Conesa del ValleGiacomo ContinJesus Guillermo Contreras NunoMaurice CoquetPietro CorteseMauro Rogerio CosentinoFilippo CostaSusanna CostanzaPhilippe CrochetMaciej Marek CzarnynogaAndrea DaineseGautam DangeMeike Charlotte DanischAndrea DanuProttay DasSupriya DasArchita Rani DashSadhana DashAnnalisa de CaroGiacinto de CataldoJan de CuvelandAlessandro de FalcoDaniele de GruttolaNora de MarcoChiara de MartinSalvatore de PasqualeRohaan DebRaffaele del GrandeLuigi Dello StrittoGeovane Grossi Araujo de SouzaPreeti Dhankher LesserDomenico Di BariMarcello Di CostanzoAntonio Di MauroBenedetto Di RuzzaBatoul DiabYanchun DingJanik DitzelRoberto DiviaAlexandru Florin DobrinBenjamin DonigusLars DopperJan Michal DubinskiAndrea DublaPascal DupieuxNatalia DzalaiovaTabea Maria EderRaymond James EhlersFlorian EisenhutRen EjimaDomenico EliaB. ErazmusFrancesca ErcolessiBruno EspagnonGiulio EulisseDavid EvansLaura FabbiettiMattia FagginJulien FaivreFeng FanWenqing FanTao FangAlessandra FantoniMarkus FaselAlessandro FelicielloGrigorii FeofilovArturo Fernandez TellezLucas Ferrandi de OliveiraMarta Bertran FerrerAndrea FerreroChiara FerreroAlessandro FerrettiVictor Jose Gaston FeuillardDmitry FinogeevFiorella FiondaAmanda Nicole FloresSiegfried Valentin FoertschIlya FokinSergey FokinUmberto FolloRobert ForynskiEnrico FragiacomoEszter FrajnaHenrik FribertUlrich FuchsNicola FunicelloChristophe FurgetArtur FursTakahiro FusayasuJens Joergen GaardhoejeMartino GagliardiAlberto Martin Gago MedinaTanu GahlautCarlos Duarte GalvanSarjeeta GamiParaskevi GanotiJose Maria Garabatos CuadradoJosue Martinez GarciaTonatiuh Garcia ChavezEdmundo Javier Garcia-SolisSara GarettiCorrado GargiuloPiotr Jan GasikHari Mohan GaurAmrit GautamMaria Beatriz de Leone GayMarie GermainRoman August GernhaeuserChandrasekhar GhoshMarco GiacaloneGiulia GioachinSourav Kanti GiriPaolo GiubellinoPiero GiubilatoPeter GlasselEwa GlimosVictor Luis Gonzalez SebastianMarek Boguslaw GorgonKangkan GoswamiSven GotovacVarlen GrabskiLukasz Kamil GraczykowskiEkaterina GreckaAlessandro GrelliCostin GrigorasVladislav GrigoryevSmbat GrigoryanOla Slettevoll GroettvikFabrizio GrosaJan Fiete Grosse-OetringhausRaffaele GrossoDavid GrundNadine Alice GruenwaldRachid GuernaneMaxime Rene Joseph GuilbaudKristjan Herlache GulbrandsenJesper Jan Walter Karlsson GumprechtTuba GundemTaku GunjiJiacheng GuoWenda GuoAnik GuptaRamni GuptaRashi GuptaKatarzyna GwizdzielLaszlo GyulaiCynthia Marie HadjidakisFakhar Ul HaiderSara HaidlovaMintu HaldarHideki HamagakiYounghoon HanBrian Gerald HanleyRyan Patrick HanniganJoachim HansenJohn William HarrisAustin Vincent HartonMichael Volker HartungAfrina HasanHadi HassanDespina HatzifotiadouPhilip HauerLaura Brittany HavenerErnst HellbarHaavard HelstrupMarvin HemmerTomas HermanSabrina Gabrielle HernandezGerardo Antonio Herrera CorralKristin Fanebust HetlandBenedict HeybeckHartmut HillemannsBoris HippolyteIsis Pihn Marie HobusFelix Willi HoffmannBas HofmanMaximilian MahleinAdrian HorzykYongzhen HouPeter Zahariev HristovPatrick HuhnLaura Maria HuhtaThomas HumanicVendulka HumlovaAlek HutsonDirk HutterMinyoung Chris HwangRadiy IlkaevMotoi InabaMikhail IppolitovArtem IsakovTommaso IsidoriMd Samsul IslamMarian IvanovMarian IvanovKaare Endrup IversenJungeol KimMiroslaw JablonskiBarbara JacakNicolo JacazioPeter Martin JacobsSlavka JadlovskaJan JadlovskySyaefudin JaelaniCristiane Jahnke Fiorini da SilvaMonika Joanna JakubowskaErnest JamroDiana Maria JanikMalgorzata Anna JanikSu-Jeong JiShihai JiaTao JiangAlom Antonio Paz JimenezShangtai JinFlorian JonasDaniel Matthew JonesJohn JowettJerome JungMichael JungAntoine Jean-Simon JuniqueAnton JuskoJetnipit KaewjaiPeter KalinakAlexander Philipp KalweitAyben Karasu UysalNikolaos KaratzenisOleg KaravichevTatiana KaravichevaMaja Jadwiga KarwowskaUdo Wolfgang KebschullMarkus KeilBernhard Franz KetzerJohannes KeulSwapnesh Santosh KhadeAhsan Mehmood KhanAlexei KhanzadeevYury KharlovAnisa KhatunArvind KhuntiaZhanna KhuranovaBjarte Wang-KilengBeomkyu KimChong KimDong Jo KimDongguk KimEun Joo KimGiyeong KimHyunwoo KimJaehyun KimJiyoung KimJunlee KimMinjung KimSe Yong KimTaejun KimKento KimuraStefan KirschIvan KiselSergey KiselevAdam Ryszard KisielJennifer Lynn KlayJochen KleinSpencer Robert KleinChristian Klein-BoesingMatthias KleinerAlexander KlugeChinorat KobdajRyotaro KoharaThorsten Sven KolleggerAndrey KondratyevNatalia KondratyevaJoshua Leon KonigPiotr Jan KonopkaGeorgui Kornakov VanMaximilian KorwieserSebastian Dominik KoryciakCornelia KosterArtem KotliarovNino KovacicVladimir KovalenkoMarek KowalskiVenelin Valeriev KozhuharovGrigory KozlovIvan KralikAdela KravcakovaLubos KrcalMarian KrivdaFilip KrizekKatarina Krizkova GajdosovaCristiano KrugMario KrugerEvgeny KryshenVit KuceraChristian Claude KuhnTakuya KumaokaDeekshit KumarLokesh KumarNavneet KumarShyam KumarSourav KunduMenghsiu KuoPodist KurashviliAlexey KurepinShunsuke KuritaAlexey KuryakinSvetlana KushpilMonika KutylaAndrey KuznetsovMin Jung KweonYoungil KwonSarah Louise La PointePaola La RoccaAnantachai LakrathokMassimo LamannaStanislas LambertAimeric Robin LandouRune LangoyElisa LaudiLukas LautnerRafael Angel Narcio LaveagaRoman LavickaRamona LeaHyungjun LeeIosif-Charles LegrandGauthier LegrasAlexian Marc LejeuneTomasz Marcin LelekIldefonso Leon MonzonMarcel Markus LeschPeter LevaiMingze LiPeiyu LiXiaomei LiBeatrice Eva Liang-GilmanJorgen Andre LienRoman LietavaIris LikmetaBong-Hwi LimHyunji LimSanghoon LimShoulong LinVolker LindenstruthChristian LippmannDominika LiskovaDonghai LiuJian LiuGianni Shigeru Setoue LiveraroIngrid Mckibben LofnesConstantinos LoizidesSandor LokosJohanna LomkerXavier Bernard LopezErnesto Lopez TorresClement LotteauPengzhong LuWeijian LuZhiyong LuFabiola Viridiana Lugo PorrasJiaqi LuoGrazia LuparelloMario Armando Talamantes JohnsonYugang MaMagnus MagerAntonin MaireEmilia Maria MajerzMartin Vasilev MakarievGiovanni MalfattoreNasir Mehdi MalikNida MalikSalman Khurshid MalikDukhishyam MallickNeelkamal MallickGiuseppe MandaglioSushobhan Kumar MandalAlexandru ManeaVladislav MankoAyan Kumar MannaFranck MansoGeorgios MantzaridisVito ManzariYaxian MaoRobert Waclaw MarcjanGiacomo Vito MargagliottiAnselmo MargottiAna Maria MarinChristina MarkertPaolo MartinengoMario Ivan Martinez HernandezGines Martinez-GarciaMaria Paula Martins PalharesSilvia MasciocchiMassimo MaseraAlberto MasoniLaure Marie MassacrierOlaf MassenAnnalisa MastroserioLorenzo MatteiSerena MattiazzoAdam Tomasz MatyjaFrancesco MazzaschiMarianna MazzilliYury MelikyanMaria Monalisa de Melo PaulinoArturo Alejandro Menchaca-RochaJesus Eduardo Munoz MendezElisa MeninnoMarius Wilm MenzelMichal MeresLuca MichelettiDarius MihaiDimitar Lubomirov MihaylovAndreas Ulveseth MikalsenKonstantin MikhaylovLouise MillotNicola MinafraDariusz Czeslaw MiskowiecAbhi ModakBedangadas MohantyMohammed Mohisin KhanMikael Andreas MolanderMriganka Mouli MondalShirajum MoniraDenise Aparecida Moreira de Godoy WillemsAndreas MorschTeo MrnjavacStefanie MrozinskiValeria MucciforaSanjib MuhuriAlice MulliriMarcelo Gameiro MunhozRobert Helmut MunzerHikari MurakamiLuciano MusaJan MusinskyJulian Wojciech MyrchaNicholas Benjamin SundstromBharati NaikAnjali Ila NambrathBasanta Kumar NandiRosario NaniaEugenio NappiAdrian Fereydon NassirpourVlad-Iulius NastaseAbhishek NathNina Francesca NathansonChristine NattrassKirill NaumovAlexandra NeaguLukas NellenRoman NepeivodaSigurd NeseNicola NicassioBorge Svane NielsenEmil Gorm NielsenSergey NikolaevVladimir NikulinFrancesco NoferiniSeoyoung NohPetr NomokonovJaime NormanNorbert NovitzkyJoakim Ingemar NystrandMatthew Robert OckletonMasanori OginoSaehanseul OhAlice Elisabeth OhlsonMasahiro OidaVitaly OkorokovJanusz OleniaczChiara OppedisanoAntonio Ortiz VelasquezHiroki OsanaiJacek Tomasz OtwinowskiMotomi OyaKen OyamaSonali PadhanDavide PaganoGuy PaicSergio Paisano GuzmanAntonio PalascianoIaroslav PanasenkoPravata PanigrahiCaterina PantouvakisHanseo ParkJonghan ParkSangwoo ParkTae Yong ParkJasper Elias ParkkilaPreet Bhanjan PatiYash PatleyRajendra Nath PatraPramil PaudelBiswarup PaulHua PeiThomas PeitzmannXinye PengMichele PennisiStefania PerciballiDmitrii PeresunkoGuillermo Mesa PerezYury PestovMihai PetroviciStefano PianoMiroslav PiknaPhilippe PillotOmbretta PinazzaLawrence PinskyChiara PintoSilvia PisanoMateusz Andrzej PloskonMirko PlaninicDamian Kacper PlociennikMartin PoghosyanBoris PolishchukStefano PolitanoNikola PoljakAmalia PopSarah Julie PorteboeufIrandheny Yoval PozosKshitish Kumar PradhanSidharth Kumar PrasadSuraj PrasadRoberto PreghenellaFrancesco PrinoClaude Andre PruneauIgor PshenichnovMaximiliano PuccioSara PucilloLuca QuagliaAswathy Menon Kavumpadikkal RadhakrishnanSimone RagoniAnanya RaiAndry Malala RakotozafindrabeNiveditha RamasubramanianLuciano RamelloCesar Omar Ramirez AlvarezMarika RasaSami Sakari RasanenRutuparna RathMax Philip RauchIvan RavasengaKenneth Francis ReadChristian ReckziegelAndreas Ralph RedelbachKrzysztof RedlichCarolina Anna JauchHector David Regules MedelAttiq Ur RehmanFelix ReidtHaakon Andre Reme-NessKlaus Johannes ReygersRiccardo RicciMatthias Rudolph RichterAnton Albert RiedelWerner RieglerAndrea Giovanni RifferoMichele RignaneseCristina RipoliCatalin-Lucian RisteaManuel Viqueira RodriguezMario Rodriguez CahuantziKetil RoeedRoman RogalevElena RogochayaDavid Michael RohrDieter RoehrichSolangel Rojas TorresPrzemyslaw Stefan RokitaGleb RomanenkoFederico RonchettiDiana Rosales HerreraEdgar Dominguez RosasKrystian RoslonAndrea RossiAnkhi RoySubhadeep RoyNicola RubiniJustus Arne RudolphDaniela RuggianoRinaldo RuiPawel Grzegorz RussekRoberto RussoAnar RustamovYury RyabovAndrzej Krzysztof RybickiLevi Colt van RyderGeonmo RyuJaehyeok RyuWioleta RzesaBianca SabiuRita SadekSamrangy SadhuSergey SadovskiySwati SahaBhagyarathi SahooRaghunath SahooDushmanta SahuPradip Kumar SahuJogender SainiKlaudia TroppShingo SakaiSanjeev Singh SambyalDaniel SamitzIsabella SannaThiago Badaro SaramelaDebojit SarkarPranjal SarmaValerio SarritzuValentina Mantovani SartiMike SasSawan SawanEugenio ScapparoneJohann Joachim SchambachHorst Sebastian ScheidClaudiu Cornel SchiauaRainer Martin SchickerFelix SchlepperAlexander SchmahChristian Joachim SchmidtMartin SchmidtNicolas SchmidtAustin Robert SchmierJan SchongarthRomain SchotterAlexander WilhelmiJurgen SchukraftKai Oliver SchwedaGilda ScioliEnrico ScomparinJanet Elizabeth SegerYuko SekiguchiDaiki SekihataMariia SelinaIlya SelyuzhenkovSerhiy SenyukovJin Joo SeoDmitry SerebryakovLeonid SerkinLaura SerksnyteAdrian SevcencoTebogo Joyce ShabaAlexandre ShabetaiRuben ShahoyanBinti SharmaDeependra SharmaHimanshu SharmaMeenakshi SharmaSheetal SharmaTonmoy SharmaUpasana SharmaAfnan ShatatOveis SheibaniKenta ShigakiMaya Hachiya ShimomuraSergey ShirinkinQiye ShouYury SibiryakSabyasachi SiddhantaTeodor SiemiarczukTiago Fiorini da SilvaWillian da SilvaDavid Olle Rickard SilvermyrTawanchat SimantathammakulRadoslav SimeonovBalwan SinghBhawani SinghKamaljeet SinghRanbir SinghRavindra SinghSweta SinghVivek SinghVikas SinghalTinku Sarkar - SinhaBranislav SitarMario SittaBernhard SkaaliGeorgijs SkorodumovsNikolai SmirnovRaimond SnellingsEmilie Haugland SolheimChristian SonnabendJorine SonneveldFrancesca SoramelAnalyce Bella Soto-HernandezRik SpijkersIwona Anna SputowskaJoey StaaJohanna StachelIonel StanTim StellhornStephan Friedrich StiefelmaierDiego StoccoIda StorehaugNicolas Justus StrangmannPeter StratmannSofia StrazziAlessandro SturnioloAlexandre Alarcon Do Passo SuaideChristophe Pierre SuireAlice-Florenta SuiuMikhail SukhanovMiljenko SuljicRishat SultanovVikash SumberiaSuharyo SumowidagdoLorenzo Hernandez TabaresSeyed Farid TaghaviJun TakahashiGanesh Jagannath TambaveZebo TangJaideep TanwarDaniel Jesus Tapia TakakiNicolae TapusLucia Anna TarasovicovaMadalina-Gabriela TarzilaArturo TauroAndrea Tavira GarciaGuillermo Tejeda MunozLivia TerlizziCristina TerrevoliDhananjaya ThakurSanchari ThakurMagnus ThoegersenDeepa ThomasNicolas TiltmannAnthony Robert TimminsAlberica ToiaRyoka TokumotoSofia TomassiniKeisuke TomohiroNataliya TopilskayaMarco ToppiVictor Valencia TorresAntonio TrifiroTriloki TrilokiAndrea Sofia TrioloSushanta TripathyTulika TripathyStefano TrogoloVictor TrubnikovWladyslaw Henryk TrzaskaTomasz Piotr TrzcinskiChristina TsolantaRan TuAlexandr TumkinRosario TurrisiTrine Spedstad TveterKjetil UllalandBerkin UlukutluSahil UpadhyayaAntonio UrasMarta UrioniGianluca UsaiMokshi VaidMartin ValaNicolo ValleLennart van DoremalenMarco van LeeuwenCasper Arie van VeenRoelof Jan Gijs van WeeldenDezso VargaZoltan VargaPaola Vargas TorresMaria VasileiouAndrey VasilievOton Vazquez DoceOmar Vazquez RuedaVladimir VecherninPaul VeenErmanno VercellinRahul VermaRobert VertesiMarta VerweijLinda VickovicZabulon VilakaziOrlando Villalobos BaillieAnna VillaniAlexander VinogradovTiziano VirgiliMaxim Mikael Olavi VirtaAlexander VodopyanovMartin Andreas VolklSergey VoloshinGiacomo VolpeBarthelemy von HallerIvan VorobyevNikita VozniukJanka VrlakovaJie WanChunzheng WangDongfang WangYuanzhe WangYubiao WangZhengqing WangAdam Tadeusz WegrzynekFelix Thomas WeiglhoferSandro Christian WenzelJohannes Peter WesselsPiotr Kazimierz WiacekJens WiechulaJon WikneGrzegorz Andrzej WilkJeremy John WilkinsonGuido Alexander WillemsBernd Stefan WindelbandJonathan Caspar WitteMaksymilian WojnarJosephina Rae WrightChuntai WuWenya WuYitao WuKegang XiongZhenjun XiongLang XuRan XuAnkur YadavArun Kumar YadavYorito YamaguchiSeunghwan YangShiming YangSatoshi YanoEmma Rose YeatsJie YiRuiqi YinZhongbao YinIn Kwon YooJin Hee YoonHyeonjin YuShiming YuanAlperen YuncuValentina ZaccoloChiara ZampolliFederica ZanoneNima ZardoshtiPetr ZavadaBiao ZhangChi ZhangLiuyao ZhangMaolin ZhangMingyu ZhangSong ZhangXiaoming ZhangYifei ZhangYuan ZhangZhen ZhangMingrui ZhaoVladimir ZherebchevskiiZhi YuDaicui ZhouYou ZhouJianhui ZhuSenjie ZhuYa ZhuAlessandra ZingarettiStefan Cristi ZugravelNicola Zurlo
• Organismes : Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique de Clermont Laboratoire de Physique de Clermont Laboratoire de physique subatomique et des technologies associées Institut Pluridisciplinaire Hubert Curien Institut Pluridisciplinaire Hubert Curien Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Physique des 2 Infinis de Lyon Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique de Clermont Laboratoire de Physique de Clermont Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique Subatomique et de Cosmologie Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Institut Pluridisciplinaire Hubert Curien Institut Pluridisciplinaire Hubert Curien Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de Physique de Clermont Institut de Physique des 2 Infinis de Lyon Institut Pluridisciplinaire Hubert Curien Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique de Clermont Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique de Clermont Laboratoire de Physique Subatomique et de Cosmologie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique de Clermont Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Physique des 2 Infinis de Lyon Institut Pluridisciplinaire Hubert Curien Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de Physique des 2 Infinis Irène Joliot-Curie Laboratoire de physique subatomique et des technologies associées Laboratoire de Physique de Clermont Institut de Physique des 2 Infinis de Lyon Institut de Recherches sur les lois Fondamentales de l'Univers Institut de Physique des 2 Infinis de Lyon Institut de Recherches sur les lois Fondamentales de l'Univers Laboratoire de Physique de Clermont

---

Résumé : Direct measurements of the $ρ^0$p interaction have remained so far elusive, with most insights derived indirectly from photoproduction or low-energy partial wave analyses. This letter presents the first direct observation of the $ρ^0$p interaction, obtained through two-particle correlations measured in high-multiplicity, ultrarelativistic proton-proton collisions at $\sqrt{s} = 13$ TeV by the ALICE Collaboration at the LHC. Two-particle correlation data, analyzed within chiral effective field theory ($χ$EFT) using a coupled-channel approach and incorporating recent $ϕ$-p data, yield a scattering length of $a_{ρ^0p} = (-0.46 \pm 0.04) + i(0.20 \pm 0.04)$ fm and constrain coupling strengths of two states identified with the N(1958) and N(1700). These findings emphasize the importance of coupled-channel dynamics and dynamically generated states in understanding the $ρ^0$p interaction. The results establish a vacuum baseline for extrapolation studies to high densities, contributing to the foundation for chiral symmetry restoration searches, and offer collider-based insights into the QCD spectrum, complementing traditional low-energy approaches. This work marks a significant advance in correlation studies, extending the exploration of interactions to the most short-lived QCD states.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 25/08/2025
• Auteurs : Brice MarcPhilippe FoucherFlorence ForbesPierre Charbonnier
• Organismes : Evaluation non destructive des structures et des matériaux Laboratoire Jean Kuntzmann Centre Inria de l'Université Grenoble Alpes Evaluation non destructive des structures et des matériaux Modèles statistiques bayésiens et des valeurs extrêmes pour données structurées et de grande dimension Evaluation non destructive des structures et des matériaux

---

Résumé : Les méthodes via Normalizing Flows (NF) sont des méthodes de détection d'anomalies non supervisées qui performent bien dans le cadre de l'auscultation des ouvrages d'art (OA). Utilisant uniquement des images sans défauts, elles apprennent à détecter les anomalies comme les éléments se démarquant de la distribution des parties saines. Dans ces travaux, nous mettons en place différents objectifs d'apprentissage complémentaires utilisant des anomalies synthétiques, générées par interpolation de POISSON, afin d'améliorer les performances du modèle NF CFlow-AD, un des meilleurs modèles NF de l'état de l'art. Nous montrons l'intérêt de ces objectifs sur plusieurs jeux de données relatifs aux OA.

---

Fichiers liés : GRETSI_2025 (10).pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/08/2025
• Auteurs : Julien MazièresFabrice BarlesiIsabelle RouquetteOlivier MolinierBenjamin BesseIsabelle MonnetClarisse Audigier-ValetteAnne-Claire ToffartPatrick Aldo RenaultSéverine FrabouletSandrine HiretBertrand MennecierDidier DebieuvreVirginie WesteelPhilippe MassonAnne Madroszyk-FlandinEric PichonAlexis CortotElodie AmourFranck MorinGérard ZalcmanDenis Moro-SibilotPierre-Jean Souquet
• Organismes : Centre Hospitalier Universitaire de Toulouse Intergroupe Francophone de Cancérologie Thoracique [Paris] Centre de Recherche en Cancérologie de Marseille Intergroupe Francophone de Cancérologie Thoracique [Paris] Assistance Publique - Hôpitaux de Marseille Service Anatomie et cytologie pathologiques [CHU Toulouse] Intergroupe Francophone de Cancérologie Thoracique [Paris] Service de pneumologie et oncologie thoracique [CH Le Mans] Intergroupe Francophone de Cancérologie Thoracique [Paris] Institut Gustave Roussy Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] CHI Créteil Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] Hôpital Michallon Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Intergroupe Francophone de Cancérologie Thoracique [Paris] Centre hospitalier de Pau Hôpital Foch [Suresnes] Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] ICO-René Gauducheau Cancer Center Nouvel Hôpital Civil de Strasbourg Centre Hospitalier Universitaire [Strasbourg] Intergroupe Francophone de Cancérologie Thoracique [Paris] Groupe hospitalier de la région de Mulhouse et Sud-Alsace Intergroupe Francophone de Cancérologie Thoracique [Paris] Centre Hospitalier Régional Universitaire de Besançon Intergroupe Francophone de Cancérologie Thoracique [Paris] Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 Intergroupe Francophone de Cancérologie Thoracique [Paris] Institut Paoli-Calmettes Intergroupe Francophone de Cancérologie Thoracique [Paris] Centre Hospitalier Régional Universitaire de Tours Intergroupe Francophone de Cancérologie Thoracique [Paris] Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] Institut de recherche sur les systèmes nucléaires pour la production d'énergie bas carbone (CEA - DES) Intergroupe Francophone de Cancérologie Thoracique [Paris] Université Paris Cité Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) Intergroupe Francophone de Cancérologie Thoracique [Paris] Centre Hospitalier Lyon Sud [CHU - HCL]
• Publié dans Clinical Cancer Research le 30/10/2020

---

Résumé :

---

Fichiers liés : 3172.pdf

---

Source